Economic evaluation of health promotion for older people-methodological problems and challenges by Huter, Kai et al.
DEBATE Open Access
Economic evaluation of health promotion
for older people-methodological problems
and challenges
Kai Huter1,2*, Ewa Kocot3, Katarzyna Kissimova-Skarbek3, Katarzyna Dubas-Jakóbczyk3 and Heinz Rothgang1,2
Abstract
Background: The support of health promotion activities for older people gains societal relevance in terms of enhancing
the health and well-being of older people with a view to the efficient use of financial resources in the healthcare sector.
Health economic evaluations have become an important instrument to support decision-making processes in many
countries. Sound evidence on the cost-effectiveness of health promotion activities would encourage support for the
implementation of health promotion activities for older people. This debate article discusses to what extent economic
evaluation techniques are appropriate to support decision makers in the allocation of resources regarding health
promotion activities for older people. We address the problem that the economic evaluation of these interventions is
hampered by methodological obstacles that limit comparability, e.g. with economic evaluations of curative measures.
Our central objective is to describe and discuss the specific problems and challenges entailed in the economic
evaluation of health promotion activities especially for older people with regard to their usefulness for informing
decision making processes.
Discussion: Beyond general problems concerning the economic evaluation of health promotion, our discussion
focusses on problems that pertain to the analysis of cost and outcomes of health promotion interventions for older
people. With regard to costs these are general problems of economic evaluations, namely the actual implementation of
a societal perspective, the appropriate measurement and valuation of informal caregiver time, the measurement and
valuation of productivity costs and costs incurred in added years of life. The main problems concerning the identification
and measurement of outcomes are related to the identification of outcome parameters that, firstly, adequately reflect
the broad effects of health promotion interventions, especially social benefits that gain importance for older people, and
secondly, ensure a comparability of effects across different age groups. In particular, the limitations of the widely used
QALY for older people are discussed and recently developed alternatives are presented.
Conclusions: The key conclusion of the article is that a comparison of the effects of different health promotion
initiatives between different age groups by means of economic evaluation is not recommendable. Taking into
account the complex outcomes of health promotion interventions it has to be accepted that the outcomes of
these interventions will often not be comparable with clinical interventions and have to be assessed differently.
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Background
As a result of demographic change and a growing pro-
portion of older people in the population, morbidity in
this group has become a highly important issue, in
particular with regard to increasing costs in the health-
care sector [1]. The support of health promotion activ-
ities for older people thus gains societal relevance in
terms of enhancing the health and well-being of older
people with a view to the efficient use of resources in
the healthcare sector [2].
Establishing the best way to deploy limited societal re-
sources and thereby maximise utility for the members of
a given society is an issue of fundamental importance.
The application of this principle in healthcare means de-
ciding which share of the available resources should go
into healthcare and its different branches and target
groups. Bearing this in mind, this debate article discusses
to what extent economic evaluation techniques are an
appropriate means to support decision makers in the al-
location of resources for health promotion activities for
older people. To achieve this, the article examines differ-
ent problems and methodological challenges of the
economic evaluation of health promotion interventions
in general – and discusses in detail problems and impli-
cations that are specific for the assessment of interven-
tions aiming at older people. With a specific focus on
health promotion for older people and on the usefulness
of health economic evaluation to inform decision-
making processes, this article thus adds to the broader
literature on possibilities and limitations of health eco-
nomic evaluation.
When political decisions about the funding of health
promotion activities for special target groups need to be
made, such activities have to be weighed up against mea-
sures for other target groups or curative measures which
may be more effective or might have similar effects. Eco-
nomic evaluation is defined by Drummond et al. as the
comparative analysis of alternative courses of action in
terms of both costs and consequences [3]. Applying this
principle to healthcare provision, health economic evalu-
ations have become an important instrument for
supporting decision-making processes in many countries
[4, 5]. Sound evidence on the cost-effectiveness of health
promotion activities would encourage support for the
implementation of health promotion activities for older
people.
The basic tasks of any economic evaluation are to
identify, measure, value and compare the costs and con-
sequences of the alternatives under consideration. A full
economic evaluation compares at least two alternatives
and examines the costs and consequences of both of
them. It applies the concept of opportunity costs, that is:
benefits forgone when opting for a specific intervention
[6]. The opportunity cost of a decision for a specific
health promotion measure is the value of benefits of the
next best alternative. Thus, economic evaluation helps
to answer the question whether a specific programme is
worth pursuing as against other programmes one could
conduct with the same resources [3].
Originally developed for clinical interventions, health
economic evaluation methods are today applied to more
complex health promotion interventions and public
health programmes. According to the WHO definition,
“health promotion” is the process of enabling people to
increase control over and improve their health. It moves
beyond a focus on individual behaviour towards a wide
range of social and environmental interventions [7].
Such strategies operate at multiple levels, including the
individual, the family, the community, and society more
generally. However, this broad focus tends to amplify
general methodological problems of economic evalua-
tions, especially the more complex and the less specific
the targets of the respective programmes become. As a
consequence, comparability with, for instance, health
economic evaluations of curative measures may be
limited.
Methodological problems pertaining to economic eval-
uations of health promotion activities in general have
been widely discussed [e.g. 8–14]; a look at existing eco-
nomic evaluations on health promotion, however, shows
that for key problems only unsatisfactory solutions have
been found. This is demonstrated for example in a
review study by Weatherly et al. [11]. Target group-
specific problems have not been discussed to a great ex-
tent so far in this context.
Nonetheless specific problems pertaining to economic
evaluations of health promotion activities for older
people are closely linked to problems concerning the
economic evaluation of health promotion activities in
general. With regard to cost-analysis the problems are
linked to general unresolved issues in health economic
evaluations that apply a societal perspective.
The aim of this paper is to map out the whole picture.
For this reason we will outline in the following general
problems of economic evaluations of health promotion
activities. Based on this we will elaborate and discuss the
specific problems and challenges that concern health
promotion activities for older people. This particularly
concerns problems of cost-analysis and the identification
and measurement of appropriate outcomes, which will
be discussed in more detail below. In relation to costing
problems we draw on debates on general methodological
challenges in health economic evaluations. This discus-
sion implies not least the question whether the applica-
tion of health economic evaluation methods might lead
to age-based rationing and in particular to discrimin-
ation against health promotion and disease prevention
for older people.
The Author(s) BMC Health Services Research 2016, 16(Suppl 5):328 Page 430 of 479
Finally, we will deduce some recommendations for the
economic evaluation of health promotion activities for
older people that particularly focus on their supportive-
ness for political decision-making processes.
Discussion
Health promotion and preventive activities for older
people comprise a wide range of activities, not all of which
are complex long-term interventions. Programmes target-
ing individuals, such as fall-prevention programmes, pose
less of a problem than population-based public health ini-
tiatives aiming more generally at promoting exercise and
healthy nutrition, because a lot more influencing factors
have to be considered. Methods for the evaluation of
screening and immunisation interventions are well de-
veloped [11]. Nonetheless, there are additional target
group-specific problems that have to be considered
when evaluating health promotion or preventive inter-
ventions for older people. Table 1 provides an overview
of the identified problems and their specific focus.
General problems pertaining to economic evaluations of
health promotion activities
Major difficulties relating to the economic evaluation of
health promotion interventions compared to clinical in-
terventions are related to the typically long time horizon
and the broader objectives and possible effects of these
interventions. These entail four key methodological
challenges, namely the attribution of effects (1), the
measurement and valuation of outcomes (2), the identifi-
cation of intersectoral costs and consequences (3), and
the incorporation of equity considerations (4) (as identi-
fied by Weatherly et al. [11]).
The problems concerning the attribution of effects are
closely linked to the above-mentioned long time horizon
of these interventions. This implies that the follow-up
period of an evaluation study has to be correspondingly
long – or modelling approaches have to be used. Inter-
ventions directed at populations are more difficult to
evaluate by randomized controlled trials, which are the
methodological gold standard when evaluating clinical
interventions [15–17]. For this reason alternative study
designs are often applied to capture the effects of an
intervention.
The problems concerning the measurement and valu-
ation of outcomes and those that pertain to the analysis
of costs have specific implications for older people; these
will be introduced and discussed in more detail in the
next section.
The incorporation of equity considerations is of special
interest because public health or health promotion inter-
ventions are often set up to counterbalance health in-
equalities. Instead of just maximizing health gains, they
aim at an equity oriented distribution of health gains.
Thus assessment criteria of health promotion interven-
tions may differ significantly from clinical interventions.
Additional problems relate to the divergence of
present costs and future benefits that are also linked to
the long time horizon. To reflect the belief that, in gen-
eral, society prefers to receive benefits sooner rather
than later, the discounting of future benefits may reduce
the effectiveness results of an intervention. In general
the characterization of uncertainty by sensitivity analyses
also has to be addressed [11, 18–22]. Last but not least
since the political, organisational, social and environ-
mental context of these programmes is often crucial
[cf. 10, 14], the transferability of the results to other con-
texts may be limited.
Table 1 Synoptic table of challenges concerning the economic
evaluation of health promotion activities for older people
Synoptic table of problems concerning the economic evaluation of
health promotion activities for older people
To differentiate the different aspects,
- general problems of health economic evaluations are in normal
lettering;
- aspects that arise mainly from the specific nature of health promotion
are presented in italics,
- aspects that gain special importance for older people are in
bold
Societal perspective recommended (in some countries generally required)
Attribution of effects
- Long time horizon (but shorter effective period for older people)
- RCTs are difficult to implement
- influence of third variables is increased;
- Long term outcomes have to be estimated
Measuring and valuing of outcomes
- Multiple endpoints
- Long causal chains (use of proxy outcomes)
- Social benefits and non-health targets gain importance
- Intersectoral consequences
- Diverging preference structures of older people
- Cost-utility analysis and cost-benefit analysis may imply age
based rationing
Identification, measurement of costs
- Measurement and valuation of informal caregiver time
- Measurement and valuation of productivity costs (including unpaid
labour)
- Costs incurred in added years of life
- intersectoral costs
Equity considerations
Discounting of benefits reduces effectiveness results
Increased level of uncertainty
Choice of comparator is difficult
Context-sensitivity – limited transferability
The Author(s) BMC Health Services Research 2016, 16(Suppl 5):328 Page 431 of 479
After providing this general overview to problems con-
cerning the economic evaluation of complex health pro-
motion interventions, we will now turn to aspects that
imply additional problems for older people as a target
group for health promotion.
Problems of identifying, measuring and valuating costs
Cost analysis, which implies the adequate identification
of costs that have to be taken into account, their meas-
urement and valuation, is one of the major components
of the economic evaluation of health interventions.
There are different types of costs to be considered in a
cost analysis, namely: resources used (costs) in the
healthcare sector, resources used in other sectors (and
covered e.g. by municipal budgets), resources or costs
incurred by the patient or programme participant and
their relatives, and productivity losses [3]. At this point
we want to highlight four aspects relating to costs that
pose methodological challenges that are not easy to re-
solve. These are: the recommended cost perspective of
the study (1), the appropriate measurement and valu-
ation of informal caregiver time (2), the measurement
and valuation of productivity costs (3) and the (health-
care) costs incurred in added years of life (4). While
these aspects are critical issues in costing methodology
of health interventions in general (as identified e.g. by
Meltzer and Smith [23], [cf. 24]), their influence may be
especially high in economic evaluations of health pro-
motion in general and for interventions aiming at older
people in particular.
Perspective of the analysis
Health economic evaluations can be conducted from dif-
ferent perspectives, chiefly that of the patient or
programme participant, the provider, the third-party
payer or society as a whole. The perspective of the ana-
lysis determines which costs and consequences are to be
included. For the economic evaluation of health promo-
tion interventions the societal perspective is generally
recommended [9, 10, 24], though in practice the analysis
is often conducted from a provider or public-payer
perspective (by national HTA-agencies) [11, 25]. None-
theless, some national guidelines generally demand the
use of the societal perspective (e.g. Netherlands and
Sweden). The societal perspective captures the value of
all changes in resources used and gained as a result of
an intervention, including informal caregiving and prod-
uctivity costs. As health promotion activities often affect
different sectors, like education, health services, long-
term care or environmental strategies, and rely on vol-
unteer work or participants’ leisure activities, evaluation
results will be biased if not all implied costs and conse-
quences are identified, even if no actual payment is
made for some of those resources. This affects especially
complex, multi-level or multi-strategy approaches. With
respect to older people this may especially concern costs
related to long-term care and unpaid work such as infor-
mal care or volunteer work. Adopting a single agency
perspective is likely to result in a partial evaluation that
may exclude major costs and benefits simply because
they fall on different sectors. To fully account for all
costs and benefits of a health promotion intervention,
intersectoral impacts have to be quantified as far as pos-
sible. If this is not possible, they should be described at
least qualitatively.
The appropriate measurement and valuation of informal
caregiver time
Caregiving costs – needed or saved due to an interven-
tion – have to be included in the cost analysis, though
often only paid caregiving is considered [4]. If the value
of informal, non-professional and non-compensated care
– provided by family members, friends or neighbours –
is disregarded, the true value of an intervention’s costs
and benefits may be underestimated. In addition to sev-
eral types of costs that are incurred to facilitate informal
care and effects on the health or well-being of the care-
giver, the time spent by a caregiver is the major element
of informal care and difficult to value. A systematic re-
view on methods used for and implications of including
informal care in applied economic evaluation shows that
to date only a small proportion of economic evaluation
studies include informal care and that no consensus ex-
ists on how to incorporate informal care. The extent of
the impact varies from study to study [26].
Correct measurement and valuation is crucial for a
complete cost analysis of interventions for older people,
who are usually both providers and receivers of informal
non-paid care – especially as it can be a defined target
of health promotion for older people to avoid depend-
ency on long-term care. Different methods of measuring
and valuing informal caregiving costs have been pro-
posed, like the proxy good method, the opportunity cost
method, the contingent valuation method (CVM), the
conjoint measurement method (CM) and the well-being
valuation method (WBM) [20, 27–31]. While the proxy
good and the opportunity cost method value the time
spent on informal care only, the CVM, CM and WBM
are based on preferences and (may) include a valuation
of effects on health and well-being as well and thus
imply a certain risk of double-counting health-effects.
A detailed discussion of the benefits and risks of
these methods for different types of economic evalu-
ation (depending on outcome measures) is provided
by Koopmanschap et al. [32]. They show quite clearly
that the way in which informal care is incorporated
needs careful consideration. Ignoring these cost as-
pects may bias economic evaluations of interventions
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for older people considerably. As older people may
receive and provide informal care the time invested
in informal care is considered in costing analysis as
(i) direct non-medical cost, which may be reduced as
a result of intervention and (ii) productivity cost, i.e.
value of time for caregiving by the participant which
is gained as a result of intervention.
The measurement and valuation of productivity costs
Productivity costs primarily represent lost economic prod-
uctivity due to death (mortality costs), or lost or impaired
ability to work or to engage in leisure activities due to
morbidity (morbidity costs) [3]. Productivity benefits or
losses can accrue to the individual in terms of individual
income, workforce activity, informal caregiving, and leis-
ure activities, or to the family in the form of reduced care-
taking costs and reduced impact on household income.
Whether and how productivity costs should be included
in health economic evaluations is widely debated, both in
theory and practice [cf. 20, 33–39].
Due to a lack of consensus on the inclusion of prod-
uctivity costs and the absence of a standard method for
estimating them, productivity costs are often disregarded
in actual economic evaluations, as testified in an out-
standing review paper by Krol et al. [39]. Whether prod-
uctivity costs should be included or not is ultimately a
normative question and depends on the normative
framework of the evaluation. A welfarist perspective will
include productivity costs; an extra-welfarist perspective
will not weight health gains against productivity costs.
There are three main approaches for measuring and
valuing productivity costs, and they were discussed ex-
tensively in the early 1990s: the human capital, the fric-
tion cost and the willingness to pay approach (WTP).
The main criticism of the human capital approach is
that it values life time in terms of individual earnings.
Thus, the human capital approach may economically
undervalue the productivity costs of older people, who
are engaged predominantly in unpaid work. Although
the WTP design can address the limitations of the hu-
man capital approach, it has been more difficult and
costly to implement and has been used in relatively few
cost studies. The concept behind the friction costs ap-
proach is that production losses due to illness may not
be as great as expected, because existing labour pools
and workplace structures can absorb some of this lost
productivity. Unlike lost time from paid work that is
measured and valued here mainly by the friction period,
the replacement of older persons’ informal caregiving (to
a beloved person or close relative) is often not feasible.
In such cases the costs caused by the reduction of their
productivity will be underestimated. The choice of which
method to use in a study will significantly influence the
overall results. Estimates based on the willingness to pay
approach, for example, are generally considerably larger
than those generated by a human capital approach. The
friction cost approach usually results in the lowest cost
of the three designs [3, 36, 37]. Beyond that, there is a
debate whether productivity consequences are included
in quality-of-life outcomes of an intervention, so double-
counting has to be taken into account [e.g. 37].
If productivity costs are included, the analysis is mostly
focused on productivity related to paid work [39]. This
focus neglects the value of the contribution to society pro-
vided by unpaid work e.g. of seniors, like volunteer work,
household work or informal care for relatives, neighbours
or children. Thus, the inclusion of productivity costs in
the economic evaluation will discriminate against seniors
if unpaid work is not included or valued notably less than
paid work. How this valuation should be done has to be
subjected to further scientific debate, for more references
to this debate see e.g. Krol et al. [40] (see also references
on informal caregiving).
Costs incurred in added years of life
There is a broad debate over whether costs that incur in
life years gained by an intervention should be included
in a health economic evaluation or not [41]. While there
is consensus that changes in future medical and non-
medical costs related to the intervention should be in-
cluded in the cost analysis, less agreement exists over
unrelated costs. In guidelines on how to conduct
economic evaluations the choice whether or not to in-
clude unrelated medical costs in life years gained is
mostly left to the analysts, or these costs are explicitly
excluded [27, 33, 41]. In the more recent theoretical de-
bate, arguments in favour of including unrelated health-
care costs are gaining support [25, 41]. Meltzer argues
that interventions that enhance life quality will be disad-
vantaged over interventions that prolong life if these
costs are not considered [42, 43]. A more general argu-
ment is that if health gains in terms of life years gained
are included in the numerator of the cost-effectiveness
ratio, respective costs have to be included for the sake of
consistency [3].
As a majority of healthcare costs accrue in the last
year of life [44] and costs in the last year of life are gen-
erally lower for older than for younger people, costs of
dying could decrease by delaying mortality [45]. Conse-
quently a life-prolonging intervention could lead to a re-
duction of future medical costs [46]. This might gain
even further relevance if future healthcare costs are
discounted to present value. On the other hand, an ex-
tended lifespan increases the probability of the occur-
rence of additional, maybe costly diseases [47].
The inclusion of costs unrelated to a health promotion
intervention for older people may imply that life-
prolonging interventions will be rated less cost-effective
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for older people, because the present value of these costs
will be higher due to its appearance in near future.
Another problem of unrelated costs in life years gained
lies in the practical issue of how to find reliable estima-
tions, or how to include these costs in general, while tak-
ing into account that healthcare expenditure depends
notably on proximity to death rather than age in particular
[41, 48]. For this reason it is generally recommended to
perform sensitivity analyses to assess the impact of unre-
lated costs in added life years on the cost-effectiveness ra-
tio; in this way, the impact of including or excluding these
costs will be demonstrated. Additionally it has to be
assessed whether sufficient reliable data on future costs
for the specific population exist.
This short overview of important aspects of cost ana-
lysis in a societal perspective illustrates that in the eco-
nomic evaluation of health promotion interventions for
older people special attention has to be paid to these as-
pects in order to avoid biased results to the disadvantage
of older people. These limitations have to be assessed
carefully to assure comparability.
Problems in health promotion outcome evaluations
Outcome evaluations comprise three main steps, regard-
less of the subject of the analysis (medical interventions,
health promotion programmes, drug therapies etc.).
These are identification, measurement, and valuation. In
the case of health promotion initiatives for older people,
specific problems occur at each of these steps.
Identification of outcomes
The identification of outcomes is not the primary task of
health economic evaluations. Health economic evalua-
tions are usually based on the analysis of outcome mea-
surements originally carried out e.g. by physicians who
identify effects according to the standards of evidence-
based medicine (EBM) [25]. The proof of the efficacy
and effectiveness of an intervention rather has to pre-
cede the health economic evaluation [3]. Specific re-
quirements of health economic evaluations consist,
firstly, in condensing the effects of an intervention to an
outcome parameter that can be compared with the costs
and, secondly, in the consideration of a time frame that
will usually exceed the observation period of a random-
ized controlled trial (RCT) [25].
The ultimate effects of health promotion activities
comprise not only health (mortality, morbidity), but also
social outcomes (quality of life, functional independence,
equity). Social outcomes may only be noticeable after a
considerable length of time. To make up for this,
changes more closely connected with health promotion
programmes are considered as proxy outcome indicators.
These can be immediate results of an intervention, or
so-called intermediate health outcomes like improved
health literacy, healthy lifestyles, social activities that affect
health determinants or the enhancement of healthy organ-
isational practices (cf. Nutbeam’s categorization [12]).
Proxy outcomes, however, have similar problems to “sur-
rogate outcomes” in clinical studies; they are substitutes
for patient-relevant endpoints, but an actual causal rela-
tionship may be difficult to prove. Clinical studies provide
many examples for assumed surrogate markers (e.g. re-
duced blood pressure) that do not ultimately affect
patient-relevant outcomes in terms of mortality, morbidity
or quality of life. Proxy outcomes need to be validated if
they are used in economic evaluations. Because effects of
health promotion interventions unfold over a long period
of time, they may be influenced by other parameters, pro-
grammes or contextual conditions. To prove in detail the
individual steps of a correspondingly long causal chain is a
challenging task for the impact evaluation of health pro-
motion activities. Proxy outcomes thus have to be used
with great caution.
Health economic evaluations usually consider changes
in the state of health or in personal benefits as relevant
outcomes, according to EBM standard relevant effects
have to be proven for individuals. This approach is suit-
able for preventive measures, but health promotion ac-
tivities aiming at non-health targets like empowerment,
social inclusion or the reduction of social inequalities
will be disadvantaged here, because these social benefits
are difficult to account for. Health promotion activities
may have significant externalities, because the impact of
a programme may affect not only the participating indi-
viduals, but also their families, friends and communities;
these are mostly assumed to be positive, but negative
side effects may be underestimated as well. Implications
of these so-called spillover effects in cost-effectiveness
analysis have been discussed and conceptualized for ex-
ample by Basu and Meltzer [49]. Equity considerations
in particular are an important issue in health promotion
and have to be taken into account [11, 50]. But targets
like these can only become relevant in health economic
evaluations if they are part of the individuals’ benefit as-
sessment (welfarist notion) or if they are explicitly and
additionally accounted for (extra-welfarist notion) [25].
A focus on health impacts only is particularly prob-
lematic in the context of health promotion interventions
for older people. For older people it is often difficult to
distinguish between health and social needs, thus the so-
cial value of a programme may be more important than
health improvement. Integration into the community,
inclusion, or increasing mobility are not always associ-
ated with an improved health status, but they can be
crucial outcomes of a health promotion programme.
Therefore, taking the “beyond health” benefits into
account is particularly important in the case of pro-
grammes for older people.
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Measurement and valuation
The measurement of health promotion outcomes is diffi-
cult in the light of the complexity and the multidimen-
sionality of effects. In health economic evaluation three
different types of outcome parameters are distinguished:
natural parameters that are used in cost-effectiveness
analysis (CEA), virtual parameters used in cost-utility
analysis (CUA), and monetary outcomes as part of a
cost-benefit analysis (CBA).
Problems concerning CEA
Natural parameters, for example weight loss, new cases
of disease that were prevented (heart attack, stroke) or
life years gained, measure only one-dimensional effects.
Their comparability is mostly limited to indication-
specific interventions and they appear to be unsuitable
for covering multidimensional or complex effects of
health promotion. The juxtaposition of several natural
outcome parameters also reduces the comparability of
different interventions.
As discussed above, proxy or surrogate parameters
that are sometimes used where direct health status im-
provements are difficult to identify have to be used with
great caution [51]. The application possibilities of CEA
are thus very limited. It is possible to evaluate preventive
measures with narrowly defined objectives, but the dis-
advantage here is that in the majority of cases results
cannot be compared across different indicators.
Problems concerning CUA
A common concept for covering the multidimensionality
of effects and achieving a comparability of different types
of interventions is the use of a comprehensive index – a
virtual parameter – that identifies, quantifies, evaluates
and sums up a variety of effects. A prominent concept
for measuring effects in healthcare is a quality of life
(QoL) index. The most commonly used indicator is the
quality adjusted life year (QALY). It takes into account
both quantitative (life extension) and qualitative (health-
related quality of life) effects of an intervention. The
QALY serves as a widely accepted reference standard for
health economic evaluations and is also commonly used
in the evaluation of health promotion interventions. Al-
though the QALY offers these distinct advantages, it en-
tails several limitations and methodological problems
that have been widely discussed [e.g. 52–55]. In concep-
tual debates it is criticised that QALYs derive from an
extra-welfarist perspective. The utility to be maximised
is determined externally by policy-makers. The relevant
dimensions (quality and time), and their linear conjunc-
tion have been set externally; they do not derive from
the individuals’ preferences. Technical problems relate
especially to the fact that different instruments to value
QoL yield different results.
Especially when it comes to the evaluation of health
promotion interventions for older people, the possible
uses of QALYs are very limited. There are four main rea-
sons why the use of QALY may discriminate against
older age groups [4], [cf. 56–59]. First, as older people –
even if they are healthy – have a lower remaining life ex-
pectancy, the possible gain in (quality-adjusted) life years
is lower compared to that of younger people. As a result,
the number of QALYs that might be “produced” by an
intervention is smaller and in consequence the interven-
tion will be less highly valued. Second, instruments that
assess QoL are usually limited to health-related quality
of life (e.g. EQ-5D, SF-36), so individual beyond-health
effects like maintaining independence or the social ef-
fects of an intervention – which, as already explained
above, are particularly important for older people, will
not be captured. Third, instruments that assess QoL
measure the quality of life regardless of age. In common
QoL indexes like EQ-5D, physical functionalities are of
particular significance, though these become less import-
ant with increasing age. The QoL of older people will be
underrated if age-dependent measures of value are not
considered. Fourth, the average health condition of older
people is poorer than that of younger people. Due to co-
morbidities the health gains that can be realised are
smaller, since even if an intervention is successful it will
not restore full health. At the same time, small health
gains are measured rather poorly by instruments used to
assess QALYs. This is a reason why health promotion in-
terventions for older people can lead to fewer measured
health benefits, and thus to a comparably less improved
quality of life, even though the objectives of an interven-
tion have been fully achieved.
Given these limitations, the QALY is not very suitable
as an outcome measure for older people. In particular
with respect to the preferences of different age groups
the underlying, oft-cited notion that “a QALY is a QALY
is a QALY” [60], has to be rejected. If it is taken into ac-
count that preferences and especially health-related pref-
erences change during the life course, quality of life
should not be measured by a universal indicator. On the
other hand, this implies that a comparison of QoL in-
dexes between different age groups is not recommend-
able, and that comparability is limited to different
interventions within the age group of older people.
Preference-based approaches are in principle suitable for
measuring multidimensional effects on an individual
level, but they have to take specific preferences of the
target group into account, and have to include social di-
mensions as well if they are to cover the effects of health
promotion interventions for older people adequately.
Different thresholds for different age groups are not a
satisfactory solution, because relevant QoL dimensions
for older people are not covered by the indicator.
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Recently developed alternatives to measure QoL of older
people
In the light of the QALY’s shortcomings, other instru-
ments have been proposed to measure QoL for older
people which are not limited to health-related QoL but
assess a broader scope of well-being. In a recent review
of QoL instruments for economic evaluations in health
and social care for older people, Makai et al. identified
four promising well-being instruments: the Ferrans and
Powers QLI, the WHO-QoL-Old, ICECAP-O and the
ASCOT. The first two instruments are widely validated,
but lack preference weights. On the other hand, prefer-
ence weights are available for ICECAP-O and the
ASCOT, but they are less widely validated [61].
The ICECAP-O (ICEpop CAPability measure for
Older people) – as one example – is a recently devel-
oped index to assess quality of life or well-being beyond
health especially for older people, and is conceptually
linked to Sen’s capability approach [62, 63]. It has been
developed on the basis of an extensive qualitative survey
about important determinants of quality of life among
older adults in the UK. The focus of the measure is on
capabilities (what people are able to do) rather than on
functioning (what people do). It consists of five attri-
butes: attachment (love and friendship), security (think-
ing about the future without concern), role (doing
things that make you feel valued), enjoyment (enjoy-
ment and pleasure) and control (independence). It is
currently being validated and tested in different set-
tings, [e.g. 64–68].
By reflecting actual value orientations of older people
and by including social aspects of well-being, the
ICECAP-O and the ASCOT are promising instruments
for measuring quality of life of older people and in par-
ticular target-dimensions of public health interventions.
However, the comparability of results is limited to differ-
ent interventions within the older age group. Since they
might also be limited in capturing health dimensions,
Makai et al. recommend the use of health measures like
the EQ-5D alongside the ICECAP-O or ASCOT to ex-
plicitly capture health benefits as well [61].
Problems concerning CBA
Another option for overcoming the limitations of natural
or QoL parameters is the monetary valuation of effects
(CBA). This can be done without subjective elements by
determining the health costs avoided. Since this would
imply that the health gain itself is attributed no value,
another means of monetisation is used more commonly
by evaluating the effects of an intervention through the
individual willingness to pay for it. The individual’s will-
ingness to pay captures different effects of an interven-
tion in one unit. It is up to the individual to balance and
weight the different values or benefits, and non-health
related effects can be included as well. This allows a
comparison of measures in different policy fields. It cor-
responds to a welfarist normative position [25].
A major problem of willingness to pay approaches in
this context is the dependency of the result on the re-
spondent. If measures are clearly limited to a defined
target group – like older people – the vote on an alloca-
tive question will be biased by the distributive conse-
quences for the respondents. Assuming divergent value
orientations of different age groups, willingness to pay
for a preventive measure for older people will not be in-
dependent of whether younger or older people are asked.
Other difficulties in the application of CBA on health
promotion interventions relate to the fact that these in-
terventions sometimes have features of public goods and
people report very low willingness to pay for them, if at
all. Moreover, willingness to pay is dependent on an in-
dividual’s ability to pay.
Though not precisely a discrete method, some authors
recommend the application of cost-consequence analyses
(CCA) especially in the field of health promotion or
public health interventions [11, 69]. Characteristic for a
CCA is that the different cost components and the vari-
ous outcomes of an intervention are presented and cal-
culated separately. It takes into account the fact that
there are different types of benefits that might be diffi-
cult to aggregate or might be assessed differently from
various perspectives. It can be described as a CEA or
CUA with multiple outcomes. CCA allows decision
makers to decide on the basis of a differentiated assess-
ment of the various effects or benefits and this allows
them to set specific priorities. Still, comparability with
other interventions is limited.
A systematic overview of the pros and cons of the dif-
ferent outcome indicators referring to different types of
economic evaluation is presented in Table 2. As the
choice of appropriate outcome indicators is of particular
importance for the economic evaluations of health pro-
motion, we put a special focus on this.
Conclusions
The starting point of this article was the question to
what extent economic evaluation techniques are an ap-
propriate means to support decision makers in the allo-
cation of resources for health promotion activities for
older people, as the evaluation of health promotion ac-
tivities for older people entails specific problems, which
have to be taken into account. Disregarding these prob-
lems could implicitly lead to discrimination against
health promotion measures for older people and thus an
age-based rationing of public healthcare. Key problems
concerning the economic evaluation of health promo-
tion activities in general and problems with a special im-
pact on older people are summarised in Table 1.
The Author(s) BMC Health Services Research 2016, 16(Suppl 5):328 Page 436 of 479
For each evaluation choices on perspective, outcomes
and costs have to be made, which influence the result.
Table 3 summarizes how results are influenced based on
certain decisions.
Based on the argumentation put forward in this paper
regarding these problems, the main conclusions can be
summarised as follows.
A key conclusion of this paper is that a comparison of
the effects of different health promotion initiatives
between different age groups by means of economic
evaluation is not recommendable.
Due to the greater complexity of the effects, health
promotion and curative interventions will seldom be
directly comparable with clinical interventions. A
major problem for the economic evaluation of health
promotion activities thus consists in the identification
or definition of appropriate outcome indicators that
are directly connected with the formulated target of
Table 2 Overview on pros and cons of different outcome indicators in economic evaluations of health promotion for older people
Outcome Indicators Cons Pros
Cost effectiveness analysis (CEA)
Natural indicators - Effects are reduced to a single parameter
- Not all effects are covered (e.g. intersectoral effects)
- Relevant health promotion outcomes are often
difficult to operationalize
- Often proxy outcomes are used (causality to
patient-relevant endpoints has to be proven)
- Comparability of different interventions is
very limited
- Depending on the operationalization mostly easy
and clearly measurable
- Disease specific comparisons are very easily possible
- Even small health gains can be documented
- Simple and straightforward comparability of the one
given indicator
Cost utility analysis (CUA)
Aggregated indicators in
general
- Aggregation of different aspects will always
represent a limited perspective
- Multidimensionality of effects can be covered
- Different types of interventions can be compared
e.g. QALY - Only health related
- Social benefits are not covered
- Intersectoral benefits are not covered
- The linear conjunction of time and quality
is set externally (not preference based)
- Limited comparability for HPA
- Small health gains are measured poorly
- Does not reflect preferences of older
people appropriately
- May discriminate against older people
- Widely accepted reference standard and well
established instrument that is used in many
economic evaluations
e.g. ICE-CAP-O - So far not widely validated
- No comparison across age groups possible
- Limited in capturing health dimensions
- Developed according to preference weights of
older people
Cost benefit analysis (CBA)
Measurement of health
costs avoided only
- Health gains or social benefits are attributed
no value
- Subjective elements are excluded




e.g. by willingness to pay
- Political reservations against monetary
valuation of health benefits
- HPA have features of public goods,
resulting in low willingness-to-pay
- Results are not independent of who is asked:
thus an age bias is possible
- Willingness to pay is dependent on ability
to pay
- Allows the comparison of measures in different
fields of policy
- Non-health benefits can be included
Cost consequence analysis (CCA)
No standalone method
CEA or CUA with
multiple endpoints
- Limited comparability of different interventions
- Complex results may be difficult to interpret
- Very transparent
- Intersectoral costs and benefits can be covered
- Contentious cost categories can be included
- Broadly spread effects are at least described
qualitatively
- Description of equity effects can be included
- Enables decision makers to decide based on a
differentiated assessment of the various effects
or benefits
- Allows the setting of specific priorities
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the intervention and ensure the comparability of dif-
ferent measures.
Aggregated indicators – like the QALY – that focus
on health-related effects only are particularly inappropri-
ate for covering the preference structures of older
people. The time component constitutes an additional
risk of discrimination against interventions for older
people. If QALYs are used, they have to be used with
great caution, and comparisons have to be limited to
comparisons within a specific age group. More research
on adequate age-specific preference-based outcome indi-
cators such as the ICECAP-O is necessary.
Proxy outcomes should be used with caution, and even
then only proxy outcomes whose effect on patient-
relevant outcomes is thoroughly proven. The monetary
valuation of effects by willingness to pay allows the in-
clusion of intersectoral effects of health promotion, but
implies the risk of age discrimination as outcomes de-
pend on the age of the respondent.
Taking into account the complex outcomes of health
promotion interventions it has to be accepted that not
all effects can be combined into a single index. Social
benefits, equity considerations, sociocultural effects can
rather be described qualitatively.
As a comparison of interventions for different age
groups is not recommendable, the resource allocation
between health promotion interventions for different
age groups is ultimately a social or political decision
that has to be made at the political level. These allo-
cation or distribution decisions cannot be deduced
directly from economic evaluations. The application
of appropriate instruments will allow a comparison of
the effects of interventions within specific age-groups.
Given the quantity of unresolved methodological
problems relating to costs, the consideration of con-
tentious cost-categories implies a high degree of un-
certainty. As the impact on interventions for older
populations may be substantial, the results of their
economic evaluation should be presented in a sensi-
tivity analysis with and without these cost categories.
The disclosure of contentious costs in a cost-consequence
analysis will allow policymakers to decide whether they
will be relevant for the decision.
If decisions over the allocation of resources between
health promotion and clinical interventions depend
on the availability of economic evaluations or cost-
effectiveness studies, economic evaluations of health
promotion activities have to be promoted. They are
feasible, but they are considerably more complex than
clinical evaluations – and they have to be assessed
differently.
The more complex and multidimensional a health
promotion activity is, the more difficult it will be to
obtain evidence on an economic evaluation that
covers all possible costs and effects; this concerns in-
terventions addressing older people all the more as
the economic evaluation entails additional problems.
This implies the risk that – if the funding of health
promotion activities is made conditional on the evi-
dence of cost-effectiveness – complex measures are
less likely to be funded.
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Table 3 Risk factors for age discrimination in the economic evaluation of health promotion for older people
Methodological options Potential discriminatory effects for older people
If … the effect will be ….
the perspective of the study is partial, societal benefits are underestimated; for older people e.g. reduced costs for long-term care.
informal caregivers time and other informal care
costs are excluded,
benefits of interventions that aim at the reduction of dependency on long-term care are
underestimated.
productivity costs are included without considering
unpaid work,
societal value of senior’s unpaid work is neglected (informal care, volunteer work, household
work).
cost incurred in added years of life unrelated to the
interventions are included,
life-prolonging interventions for older people will be rated less cost effective, because older
people will produce more costs in near future due to comorbidities.
effects are measured by natural parameters (CEA), social benefits that are more important for older people are not covered.
effects are measured by QALYs (CUA), benefits of interventions for older people will be underestimated, because
… preferences of older people, especially social benefits are not covered.
… a lower life expectancy results in less QALYs gained.
benefits are valued as monetary outcomes by
willingness-to-pay (CBA),
results will be biased depending on distributive effects on the respondent, interventions for
older people may be rated poorly if respondents are younger people.
benefits are valued monetarily without subjective
elements (CBA),
benefits of the intervention will be underestimated, because social benefits are especially
important for older people.
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